Cargando…

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency of Tregs and effector Tregs was evident at diagnosis, together with increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Patrick, Dillon, Richard, Radia, Deepti, McLornan, Donal, Woodley, Claire, Asirvatham, Susan, Raj, Kavita, Curto‐Garcia, Natalia, Saunders, Jamie, Kordasti, Shahram, Harrison, Claire, de Lavallade, Hugues
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544983/
https://www.ncbi.nlm.nih.gov/pubmed/35802024
http://dx.doi.org/10.1111/bjh.18302
_version_ 1784804719583035392
author Harrington, Patrick
Dillon, Richard
Radia, Deepti
McLornan, Donal
Woodley, Claire
Asirvatham, Susan
Raj, Kavita
Curto‐Garcia, Natalia
Saunders, Jamie
Kordasti, Shahram
Harrison, Claire
de Lavallade, Hugues
author_facet Harrington, Patrick
Dillon, Richard
Radia, Deepti
McLornan, Donal
Woodley, Claire
Asirvatham, Susan
Raj, Kavita
Curto‐Garcia, Natalia
Saunders, Jamie
Kordasti, Shahram
Harrison, Claire
de Lavallade, Hugues
author_sort Harrington, Patrick
collection PubMed
description The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency of Tregs and effector Tregs was evident at diagnosis, together with increased expression of T‐cell exhaustion markers, including in regulatory T cells at diagnosis and in patients with refractory disease. Plasma analysis revealed significantly increased levels of cytokines including tumour necrosis factor (TNF)‐a and interleukin (IL)‐6 at diagnosis, in keeping with a pro‐inflammatory state prior to treatment. We hence demonstrate T‐cell exhaustion and a pro‐inflammatory state at diagnosis in CML, likely secondary to leukaemia‐associated antigenic overload associated with increased disease burden.
format Online
Article
Text
id pubmed-9544983
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95449832022-10-14 Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype Harrington, Patrick Dillon, Richard Radia, Deepti McLornan, Donal Woodley, Claire Asirvatham, Susan Raj, Kavita Curto‐Garcia, Natalia Saunders, Jamie Kordasti, Shahram Harrison, Claire de Lavallade, Hugues Br J Haematol Haematological Malignancy–Biology The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency of Tregs and effector Tregs was evident at diagnosis, together with increased expression of T‐cell exhaustion markers, including in regulatory T cells at diagnosis and in patients with refractory disease. Plasma analysis revealed significantly increased levels of cytokines including tumour necrosis factor (TNF)‐a and interleukin (IL)‐6 at diagnosis, in keeping with a pro‐inflammatory state prior to treatment. We hence demonstrate T‐cell exhaustion and a pro‐inflammatory state at diagnosis in CML, likely secondary to leukaemia‐associated antigenic overload associated with increased disease burden. John Wiley and Sons Inc. 2022-07-08 2022-09 /pmc/articles/PMC9544983/ /pubmed/35802024 http://dx.doi.org/10.1111/bjh.18302 Text en © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Haematological Malignancy–Biology
Harrington, Patrick
Dillon, Richard
Radia, Deepti
McLornan, Donal
Woodley, Claire
Asirvatham, Susan
Raj, Kavita
Curto‐Garcia, Natalia
Saunders, Jamie
Kordasti, Shahram
Harrison, Claire
de Lavallade, Hugues
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
title Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
title_full Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
title_fullStr Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
title_full_unstemmed Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
title_short Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
title_sort chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted t‐cell phenotype
topic Haematological Malignancy–Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544983/
https://www.ncbi.nlm.nih.gov/pubmed/35802024
http://dx.doi.org/10.1111/bjh.18302
work_keys_str_mv AT harringtonpatrick chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT dillonrichard chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT radiadeepti chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT mclornandonal chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT woodleyclaire chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT asirvathamsusan chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT rajkavita chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT curtogarcianatalia chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT saundersjamie chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT kordastishahram chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT harrisonclaire chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype
AT delavalladehugues chronicmyeloidleukaemiapatientsatdiagnosisandresistanttotyrosinekinaseinhibitortherapydisplayexhaustedtcellphenotype